Clinical trial
Comparison of Two Patient Education Methods in Women With Chronic Low Back Pain: Online Pain Education vs. AI-Driven Patient Education on Pain Beliefs, Catastrophizing, and Self-Efficacy
NCT07916597 is registered in ClinicalTrials.gov with Amasya University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Comparison of Two Patient Education Methods in Women With Chronic Low Back Pain: Online Pain Education vs. AI-Driven Patient Education on Pain Beliefs, Catastrophizing, and Self-Efficacy
- Lead sponsor
- Amasya University
- Phase
- Not applicable
- Overall status
- Not yet recruiting
- Start date
- December 1, 2026
- Completion date
- January 1, 2028
- Enrollment
- 60 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
chronic low back pain (clbp)
Arms
As registered; 2 arms.
-
Patient Education Group
-
ChatGPT Group
Primary endpoints
Registered primary outcome measures; 6 primary.
-
Pain Beliefs Questionnaire
Participants' pain beliefs will be evaluated using the Pain Beliefs Questionnaire. The scale uses a 6-point Likert-type rating ranging from 0 to 5 (never, rarely, sometimes, often, almost always, and always) and consists of 12 items. Two subscale scores are obtained from the questionnaire: psychological pain belief and organic pain belief. A higher score indicates a higher pain belief related to that subscale, whereas a lower score indicates a lower pain belief. The validity and reliability study of the scale has been conducted.
-
Pain Catastrophizing Scale
Participants' level of pain catastrophizing will be evaluated using the Pain Catastrophizing Scale (PCS). The PCS is a 13-item Likert-type self-report scale. Each item is rated on a 0-4 scale. The total score ranges from 0 to 52. It comprises three subscales: rumination, magnification, and helplessness. Higher scores indicate higher levels of catastrophizing. The validity and reliability study of the scale has been conducted.
-
Pain Self-Efficacy Questionnaire
Participants' level of pain-related self-efficacy will be evaluated using the Pain Self-Efficacy Questionnaire (PSEQ). Based on Bandura's concept of self-efficacy, the questionnaire is a 10-item self-report tool designed to measure the degree of confidence in performing a range of activities despite pain. Among questionnaires evaluating pain self-efficacy, it is a practical tool due to its brevity, possesses well-proven validity and reliability, and measures multiple domains of self-efficacy related to social and physical functioning. Each item is rated on a 7-point Likert-type scale (0: Not at all confident, 6: Completely confident). The total score ranges from 0 to 60, with higher scores indicating greater self-efficacy for functionality despite pain. The validity and reliability study of the questionnaire has been conducted.
-
Pain Beliefs Questionnaire
Participants' pain beliefs will be evaluated using the Pain Beliefs Questionnaire. The scale uses a 6-point Likert-type rating ranging from 0 to 5 (never, rarely, sometimes, often, almost always, and always) and consists of 12 items. Two subscale scores are obtained from the questionnaire: psychological pain belief and organic pain belief. A higher score indicates a higher pain belief related to that subscale, whereas a lower score indicates a lower pain belief. The validity and reliability study of the scale has been conducted.
-
Pain Catastrophizing Scale
Participants' level of pain catastrophizing will be evaluated using the Pain Catastrophizing Scale (PCS). The PCS is a 13-item Likert-type self-report scale. Each item is rated on a 0-4 scale. The total score ranges from 0 to 52. It comprises three subscales: rumination, magnification, and helplessness. Higher scores indicate higher levels of catastrophizing. The validity and reliability study of the scale has been conducted.
+1 more primary endpoint
Lead sponsor's other trials
Amasya University, most recent start first.
+75 more trials
Similar trials
Same condition (Agnosia) and phase, most recent start first.
+1,650 more trials See the condition page